Medtronic's first-quarter results warning sends shares sliding
This article was originally published in Clinica
The slowdown in the US implantable cardioverter defibrillator (ICD) market has taken its toll on Medtronic, as the world's largest medical device manufacturer warned investors that its first-quarter revenues for fiscal 2007 will not be meeting analysts' expectations.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.